| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/23/2006 | US20060040855 Low efficacy gonadotropin agonists and antagonists |
| 02/23/2006 | US20060040854 Testing the sample for abnormal, insulin-6 underexpression expression relative to a control |
| 02/23/2006 | US20060040853 Methods and compositions useful for modulation of angiogenesis using protein kinase Raf and Ras |
| 02/23/2006 | US20060040852 IL-1 antagonist formulations |
| 02/23/2006 | US20060040851 Gag-peptide complex |
| 02/23/2006 | US20060040850 Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states |
| 02/23/2006 | US20060040371 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
| 02/23/2006 | US20060040363 Human antibodies derived from immunized xenomice |
| 02/23/2006 | US20060040362 Recombinant human Mannan-Building Proteins |
| 02/23/2006 | US20060040360 Adipocyte complement related protein homolog zacrp7 |
| 02/23/2006 | US20060040358 IGF-1 receptor interacting proteins |
| 02/23/2006 | US20060040357 Novel nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, ATPase molecules, acyltransferase molecules, pyridoxal-phosphate dependant enzyme molecules and uses therefor |
| 02/23/2006 | US20060040348 Methods for producing and purifying recombinant alpha-L-iduronidase |
| 02/23/2006 | US20060040324 Methods for making metallopeptides and metallopeptide libraries |
| 02/23/2006 | US20060040316 Using transforming growth factor-beta -activated kinase-1 (TAK-1) and TAK1 binding protein 1(TAB-1) as evaluative tool in detection of modulators of interleukin and tumor necrosis factor activities |
| 02/23/2006 | US20060040314 Methods for screening polypeptides |
| 02/23/2006 | US20060040313 Human chemokine beta-9 |
| 02/23/2006 | US20060040312 Uses of kappa-conotoxin PVIIA |
| 02/23/2006 | US20060040307 A recombinant human telomerase reverse transcriptase (hTRT) protein; drug screening for antiproliferative agents that inhibit hTRT activity; cancer diagnosis and prognosis; anticarcinogenic agents |
| 02/23/2006 | US20060040302 Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors |
| 02/23/2006 | US20060040269 Cytotoxic factors for modulating cell death |
| 02/23/2006 | US20060040267 Transcriptional activator |
| 02/23/2006 | US20060040266 Diagnostics and therapeutics for diseases associated with neuromedin u2 receptor (nmu2) |
| 02/23/2006 | US20060040265 Regulation of novel human asparagine-hydroxylases |
| 02/23/2006 | US20060040259 Administering an inhibitor of prenyl cysteine methyltransferase; inhibiting the prenylation or a post-prenylation reaction of a protein contained in the virus infecting a subject |
| 02/23/2006 | US20060040025 Milk protein isolate and method for preparing same |
| 02/23/2006 | US20060039995 Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning |
| 02/23/2006 | US20060039987 Method and apparatus for producing dry particles |
| 02/23/2006 | US20060039970 Tamper-resistant oral opioid agonist formulations |
| 02/23/2006 | US20060039962 Amphiphilic compounds and vesicles liposomes for organ-specified drug targeting |
| 02/23/2006 | US20060039953 Water soluble polymer such as pullulan and an antimicrobial effective amount of thymol, methyl salicylate, eucalyptol and/or menthol; killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath |
| 02/23/2006 | US20060039947 Biologically active implants |
| 02/23/2006 | US20060039930 Methods for enhancing wound healing |
| 02/23/2006 | US20060039925 Mutants of streptococcal toxin a and methods of use |
| 02/23/2006 | US20060039922 Streptococcal heat shock proteins of the Hsp60 family |
| 02/23/2006 | US20060039918 Stress proteins and peptides and methods of use thereof |
| 02/23/2006 | US20060039917 Method for treating phantom pain by peripheral administration of a neurotoxin |
| 02/23/2006 | US20060039916 Method for treating complex regional pain by peripheral administration of a neurotoxin |
| 02/23/2006 | US20060039914 Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
| 02/23/2006 | US20060039911 Method for the treatment of gastroesophageal reflux disease |
| 02/23/2006 | US20060039909 Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes |
| 02/23/2006 | US20060039905 Galectin 11 |
| 02/23/2006 | US20060039903 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 02/23/2006 | US20060039898 Method of skin care and/or treatment using rice (Oryza sativa) hemoglobin or other hexacoordinated, non-symbiotic plant hemoglobins |
| 02/23/2006 | US20060039893 Expression vector includes insert of dna which codes for exogenous protein and adenovirus dna having deletion from nucleotides 356-4020; production of recombinant proteins; gene therapy against tumors and cancer |
| 02/23/2006 | US20060039892 Interferon- gamma -inducing factor (IGIF); for treatment of skin wounds, surgical wounds, leg ulcers, diabetic ulcers, gastrointestinal mucositis, oral mucositis, and lung injury |
| 02/23/2006 | US20060039884 Baldness related gene and the polypeptide encoded thereby , and uses |
| 02/23/2006 | US20060039883 Biologically active compounds for the modification of bodily odours |
| 02/23/2006 | US20060039870 Pulmonary delivery of enzymatic medical countermeasures |
| 02/23/2006 | US20060039862 Identification and use of growth hormone secretagogue receptor type 1A antagonists |
| 02/23/2006 | DE20023745U1 Method of modulating expression of an endogenous cellular gene in a cell to prevent gene activation or prevent repression of gene expression comprising contacting a target sequence with a zinc finger protein |
| 02/23/2006 | DE102004040452A1 Peptidgemisch Peptide mixture |
| 02/23/2006 | CA2799413A1 Therapeutic composition with a botulinum neurotoxin |
| 02/23/2006 | CA2619779A1 Use of a pde5 inhibitor for treating and preventing hypopigmentary disorders |
| 02/23/2006 | CA2600906A1 New peptidic and peptidoid bradykinin b1 receptor antagonists and uses thereof |
| 02/23/2006 | CA2592521A1 Modified vitamin k dependent polypeptides |
| 02/23/2006 | CA2579764A1 Methods of regulating differentiation and treating of multiple myeloma |
| 02/23/2006 | CA2578529A1 Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists |
| 02/23/2006 | CA2577995A1 Peptide inhibitors of c-jun dimerization and uses thereof |
| 02/23/2006 | CA2577883A1 Tnf-binding protein-1 in the treatment of psoriasis |
| 02/23/2006 | CA2577597A1 Methods of diagnosis and treatment of m. tuberculosis infection and reagents therefor |
| 02/23/2006 | CA2577386A1 Pulmonary delivery of a nerve agent neutralizing enzyme |
| 02/23/2006 | CA2577213A1 Use of gsk-3 inhibitors for the treatment of prostate cancer |
| 02/23/2006 | CA2577183A1 Mutated hiv nef for modulating immunity |
| 02/23/2006 | CA2577046A1 Chemokine combinations to mobilize progenitor/stem cells |
| 02/23/2006 | CA2577039A1 Aqueous enzyme delivery system |
| 02/23/2006 | CA2576852A1 Apparatus and method for transdermal delivery of natriuretic peptides |
| 02/23/2006 | CA2576672A1 Prevention and treatment of synucleinopathic and amyloidogenic disease |
| 02/23/2006 | CA2576526A1 Promotion of axonal regeneration with ngl-1 or agonist thereof |
| 02/23/2006 | CA2576238A1 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues |
| 02/23/2006 | CA2576049A1 Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning |
| 02/23/2006 | CA2576030A1 Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
| 02/23/2006 | CA2575563A1 Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| 02/23/2006 | CA2575387A1 Novel peptide and pharmaceutical composition containing said peptide |
| 02/23/2006 | CA2575370A1 Methods for treating premature infants |
| 02/23/2006 | CA2575058A1 Antimicrobial peptides comprising an arginine- and/or lysine-containing motif |
| 02/23/2006 | CA2574045A1 Medical device for delivering biologically active material |
| 02/23/2006 | CA2573720A1 Netrin-related compositions and uses |
| 02/23/2006 | CA2573562A1 Compositions and methods related to heart failure |
| 02/23/2006 | CA2558289A1 Peptides for the treatment of herpes virus infections |
| 02/23/2006 | CA2478456A1 Combination therapy |
| 02/22/2006 | EP1627918A1 Antagonists of interleukin-15 |
| 02/22/2006 | EP1627886A1 Polypeptide, cDNA encoding the same, and use of them |
| 02/22/2006 | EP1627885A1 Polypeptide capable of assisting digestive organ absorption |
| 02/22/2006 | EP1627884A1 Process for producing dipeptides |
| 02/22/2006 | EP1627880A1 Boronic ester and acid compounds, synthesis and uses |
| 02/22/2006 | EP1627643A2 Vascular endothelial cell growth factor antagonists |
| 02/22/2006 | EP1627642A2 Zinc free insulin crystals for use in pulmonary compositions |
| 02/22/2006 | EP1627067A1 Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b |
| 02/22/2006 | EP1627047A2 Methods for facilitating recovery of functions of endogenous or implanted or transplanted stem cells using high molecular weight hyaluronic acid |
| 02/22/2006 | EP1626983A2 Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof |
| 02/22/2006 | EP1626955A1 Captopril derivatives |
| 02/22/2006 | EP1626746A2 Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin |
| 02/22/2006 | EP1626736A1 C1 inhibitor with short half-life for transient treatment |
| 02/22/2006 | EP1626735A2 Compound and method for regulating plasminogen activation and cell migration |
| 02/22/2006 | EP1626734A2 Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections |
| 02/22/2006 | EP1626732A2 Means for preventing and treating cellular death and their biological applications |
| 02/22/2006 | EP1626696A2 Novel fibroblast growth factors and methods of use thereof |
| 02/22/2006 | EP1537211A4 Isolated cytokine receptor licr-2 |
| 02/22/2006 | EP1463516A4 Identification and characterization of multiple splice variants of the mu opioid receptor gene |